A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Inclusion Criteria: 1. Sign the informed consent form voluntarily and follow the protocol requirements; 2. Gender is not limited; 3. Age: ≥18 years old and ≤75 years old; 4. Expected survival time ≥3 months; 5. Patients with histologically and/or cytologically confirmed locally advanced or metastatic solid tumors such as non-small cell lung cancer and nasopharyngeal carcinoma; 6. Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years; 7. At least one measurable lesion meeting the RECIST v1.1 definition was required; 8. ECOG 0 or 1; 9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0; 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; 11. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the level of organ function must meet the requirements; 12. Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time≤1.5 ULN; 13. Urinary protein ≤2+ or ≤1000mg/24h; 14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment. Exclusion Criteria: 1. For stage 3 Cohort\_A, patients with MET 14 exon skipping detected by gene sequencing report before signing informed consent; 2. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil; 3. Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis; 4. Use of immunomodulatory drugs within 14 days before the first dose of study drug; 5. History of severe heart disease; 6. QT prolongation, complete left bundle branch block, III degree atrioventricular block; 7. Systemic corticosteroids or immunosuppressive agents are required within 2 weeks before study dosing; 8. Active autoimmune and inflammatory diseases; 9. Other malignancies diagnosed within 5 years before the first dose; 10. Hypertension poorly controlled by two antihypertensive drugs; 11. Pulmonary disease was defined as grade ≥3 according to CTCAE v5.0; Patients with current or history of ILD; 12. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; 13. Patients with a large amount of serous cavity effusion, or serous cavity effusion with symptoms, or within 4 weeks before signing informed consent; 14. Patients with active central nervous system metastases; 15. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipients of the test drug; 16. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation; 17. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection; 18. Active infection requiring systemic therapy; 19. Had participated in another clinical trial within 4 weeks before the first dose; 20. The investigator did not consider it appropriate to use other conditions for participation in the trial.